This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why You Should Add Encompass Health (EHC) to Your Portfolio Now
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth on the back of robust demand for effective inpatient rehabilitation services, joint ventures and solid cash reserves.
LeMaitre Vascular (LMAT) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
LeMaitre (LMAT) delivered earnings and revenue surprises of 12.82% and 3.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management
by Zacks Equity Research
AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) due to the strength of its Neurosurgery and Cardiovascular portfolios.
Here's Why You Should Hold BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
BD's (BDX) slew of product launches and strategic deals raises optimism about the stock.
Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio
by Zacks Equity Research
Baxter (BAX) unveils its five injectable products, which strengthen its emphasis on unique products and expand the pharmaceutical portfolio of the business in important therapeutic areas.
Here's Why You Should Add DaVita (DVA) to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its kidney care raises optimism about the stock.
Reasons to Hold Baxter International (BAX) in Your Portfolio
by Zacks Equity Research
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, raises optimism.
Why You Should Add Ensign Group (ENSG) to Your Portfolio Now
by Zacks Equity Research
Ensign Group (ENSG) remains well-poised for growth on sustained top-line growth, a growing healthcare portfolio and solid operating cash flows.
Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
BD's (BDX) Latest Product to Offer Wider Access to Researchers
by Zacks Equity Research
The latest worldwide commercial availability of BD's (BDX) cell sorters is set to expand researchers' capabilities to transform research and cell-based therapeutic development across numerous fields.
Here's Why Investors Should Hold Teladoc (TDOC) Stock Now
by Zacks Equity Research
Teladoc's (TDOC) Integrated Care business is expected to gain from margin expansion and improving chronic care program enrollment.
Compelling Reasons to Hold on to UnitedHealth Group (UNH) Stock
by Zacks Equity Research
UnitedHealth Group (UNH) remains well-poised for growth on the back of improved premiums, acquisitions and partnerships, an in-demand telehealth services suite and solid cash-generating abilities.
New Strong Buy Stocks for March 21st
by Zacks Equity Research
ANF, HENKY, PRLB, LMAT and GATX have been added to the Zacks Rank #1 (Strong Buy) List on March 21, 2023.
Encompass Health (EHC) Up 42% in a Year: What Lies Ahead?
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth on the back of sustained top-line growth, an expanding healthcare facility portfolio and robust cash-generating abilities.
Best Momentum Stocks to Buy for March 13th
by Zacks Equity Research
ANF, LMAT and CRH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 13, 2024.
New Strong Buy Stocks for March 13th
by Zacks Equity Research
SBSI, EBMT, LMAT, ANF and FHI have been added to the Zacks Rank #1 (Strong Buy) List on March 13, 2024.
Best Momentum Stocks to Buy for March 7th
by Zacks Equity Research
TOL, WILYY and LMAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 7, 2023.
Ensign Group (ENSG) Buys Nursing Units, Boosts U.S. Footprint
by Zacks Equity Research
Ensign Group (ENSG) acquires two skilled nursing facilities in Colorado and one similar facility in Kansas to better serve the regions' patients and grow its healthcare portfolio.
LeMaitre Vascular (LMAT) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does LeMaitre Vascular (LMAT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Best Momentum Stocks to Buy for March 5th
by Zacks Equity Research
LMAT, SPXC and BBVA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 5, 2023.
LeMaitre (LMAT) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
LeMaitre (LMAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MDT vs. LMAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MDT vs. LMAT: Which Stock Is the Better Value Option?
LeMaitre Vascular (LMAT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SurModics (SRDX) Reports Break-Even Earnings for Q1
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 100% and 3.23%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?